TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
ALVO

Alvotech

Healthcare · Drug Manufacturers - Specialty & Generic

4.20$ -10.3% vs. previous close Closing price · As of: Nov 13, 2026

Ownership

Ownership Structure

Who owns Alvotech (ALVO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 39.5% of the shares are freely tradable; institutional investors hold 5.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 5.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 54.5%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 39.5%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 357Mio.

Largest Shareholders

Funds

Funds ALVO
Name Stake (%) Shares Change (%) Date
Vanguard Total Intl Stock Index Inv 0.73 2,593,646 +55.2 09/30/2026
Vanguard Emerging Mkts Stock Idx Inv 0.58 2,064,472 +28.2 09/30/2026
iShares Biotechnology ETF 0.38 1,354,337 -0.2 10/30/2026
Stefnir Icelandic Growth 0.22 792,015 -10.8 09/30/2026
L&G Frontier Markets Eq Z USD Acc 0.21 735,465 +12.3 09/30/2026
Eaton Vance Glbl Macro Abs Ret Advtg I 0.17 593,154 +0.0 07/31/2026
Vanguard FTSE All-Wld ex-US ETF 0.12 420,533 +52.5 09/30/2026
iShares Genomics Immnlgy & Hlthcr ETF 0.09 325,825 +0.0 10/30/2026
iShares Nasdaq US Biotech ETF USD Acc 0.08 288,934 +0.2 10/30/2026
Schwab Emerging Markets Equity ETF™ 0.05 182,193 +0.0 10/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?